{"id":"doi:10.1002/hed.70306","kind":"review","title":"Treatment-Related Adverse Events and Health-Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review","authors":["O'Donnell ND","Ward EC","Wishart LR","Perera R","Barrett C","Edmiston KA","Mitchell E","Pigott A","Pitt R","Russell K","Chan BA","Ladwa R"],"author_count":12,"year":2026,"published":"2026-06-01","venue":"Head & neck","cited_by":0,"doi":"10.1002/hed.70306","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1002/hed.70306","archive_url":"https://space-kitty.com/papers/doi:10.1002/hed.70306","updated":null,"pmid":"42226019","pmcid":"PMC13653308","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC13653308/pdf","abstract":"Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill-defined. Hence, known treatment-related adverse events (TRAEs) and health-related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care services. Methods Scoping review including 98 studies. Results Moderate-severe TRAEs occurred at < 10% incidence, with most experiencing mild impacts. Dermatologic, endocrine, pulmonary, hepatic, gastrointestinal, and constitutional complaints were reported in > 40% of studies, with most symptoms occurring during treatment. ICI monotherapy had less reported toxicity than multimodality treatments. Adding ICIs to multimodality treatment creates a minimal increase in TRAEs. HRQoL scores were low, with little change during ICI treatment. Conclusions ICIs for HNSCC are generally well tolerated; however, TRAEs are common and may carry long-term functional consequences. Flexible supportive care pathways are needed to assist early detection and individualized management of functional impacts to optimize survivorship.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Treatment-Related Adverse Events and Health-Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review\" by O'Donnell ND, Ward EC, Wishart LR et al., https://doi.org/10.1002/hed.70306, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}